An Open-Label Phase 2 Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
6 month survival
United States: Food and Drug Administration
PTH-320
NCT00116389
Name | Location |
---|---|
Baylor College of Medicine | Houston, Texas 77030 |
Monmouth Medical Center | Long Branch, New Jersey 07740-6395 |
Mary Crowley Medical Research Center | Dallas, Texas 75246 |
Cancer Care Northwest | Spokane, Washington 99202 |
Providence Portland Medical Center | Portland, Oregon 97213-3635 |
Lawrence M. Stallings, MD | Wooster, Ohio 44691 |
Hematology-Oncology Associates of Rockland | Nyack, New York 10956 |
Cancer Center of the Carolinas | Greenville, South Carolina 29615 |
Indiana Oncology Hematology Consultants | Indianapolis, Indiana 46202 |
Cancer Center of Florida | Ocoee, Florida 34761 |
Dayton Oncology and Hematology | Kettering, Ohio |
Billings Clinic | Billings, Montana 59107-7000 |
Gulfcoast Oncology Associates | St. Petersburg, Florida 33705 |
Elkins Pancreas Center | Houston, Texas 77030 |
Palm Beach Institute of Hematology and Oncology | Boynton Beach, Florida 33435 |
Huron Medical Center | Port Huron, Michigan 48067 |
Northwest Alabama Cancer Center, PC | Florence, Alabama 35630 |
Oncology Associates, PC | Hartford, Connecticut 06106 |
Hematology Oncology Associates of Central Brevard | Rockledge, Florida 32955 |
Yagnesh V. Oza, MD | Mt. Vernon, Illinois 62864 |
Cancer Care Center, Inc. | New Albany, Indiana 47150 |
Medical Oncology LLC | Baton Rouge, Louisiana 70809 |
New York Oncology Hematology/Albany Regional Cancer Center | Albany, New York 12208 |
Trilogy Cancer Center | Wooster, Ohio 44691 |
Oregon Clinic, The | Portland, Oregon 97213 |
Texas Oncology, PA, Presbyterian | Dallas, Texas 75231 |
Saint Luke’s Episcopal Hospital | Houston, Texas 77030 |